Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04985032 · ClinicalTrials.gov registry record

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)

A clinical trial of Ductal Carcinoma In Situ and Invasive Ductal Carcinoma of Female Breast, sponsored by RPCR.

Recruiting
Registry status
200
Enrollment target
2
Study locations

NCT04985032: Recruiting study of Ductal Carcinoma In Situ and Invasive Ductal Carcinoma of Female Breast, sponsored by RPCR.

NCT04985032 is a study of Ductal Carcinoma In Situ and Invasive Ductal Carcinoma of Female Breast that is actively recruiting participants, run by RPCR. The registered enrollment target is 200 participants, below the 244-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (18% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04985032, a study of Ductal Carcinoma In Situ and Invasive Ductal Carcinoma of Female Breast, is actively recruiting participants, sponsored by RPCR.

RECRUITING
Registry status
200 participants
Enrollment target
2
Study locations

Study Summary

This is a multi-institutional, prospective, observational registry investigating the safety and efficacy of Accelerated Partial Breast Irradiation (APBI) using a Stereotactic Body Radiation Therapy (SBRT) delivery technique that incorporates real-time image guidance, noncoplanar fields, and respiratory tracking. The study will accrue 200 patients who will be treated to a dose of 30 Gy over the course of 5 fractions. These subjects will then have a follow up time of 5 years

Primary Outcome

physician and patient assessment of breast cosmetic result following SBRT

Interventions

  • RADIATION stereotactic body radiation therapy

Study Locations (2)

Florida

  • CyberKnife Center of South Florida in Stuart - Stuart
  • CyberKnife Centers of Tampa Bay - Tampa

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2022-08-15
Est. Completion 2027-06
RPCR

1 total trials

What NCT04985032 shows while recruiting

NCT04985032 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 244-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (18% lower).

The record links to 2 conditions, with Ductal Carcinoma In Situ appearing as the primary indexed condition, and to 1 intervention - of which stereotactic body radiation therapy is the first listed.

NCT04985032 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04985032 about?

NCT04985032 is a clinical study titled "Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)". This is a multi-institutional, prospective, observational registry investigating the safety and efficacy of Accelerated Partial Breast Irradiation (APBI) using a Stereotactic Body Radiation Therapy (SBRT) delivery technique that incorporates real-time image guidance, noncoplanar fields, and respirat...

What is the current status of trial NCT04985032?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-08-15. Estimated completion is 2027-06.

What conditions does trial NCT04985032 study?

This clinical trial studies the following conditions: Ductal Carcinoma In Situ, Invasive Ductal Carcinoma of Female Breast.

What interventions are being tested in trial NCT04985032?

The interventions under investigation include: stereotactic body radiation therapy (RADIATION).

Who is sponsoring clinical trial NCT04985032?

This trial is sponsored by RPCR, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04985032 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ductal Carcinoma In Situ

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04985032's enrollment target sits among peer trials

200 5th of 15 higher than 10 of 15 other Ductal Carcinoma In Situ trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ductal Carcinoma In Situ trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04985032, the US trial registry maintained by the National Library of Medicine. NCT04985032 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.